STOCKHOLDERS EQUITY | NOTE 9 – STOCKHOLDERS’ EQUITY In June 2020, our Board of Directors and stockholders holding a majority of the outstanding shares of our voting securities approved a resolution authorizing our Board of Directors to effect a reverse stock split of our common stock at a certain exchange ratios from 1:10 to 1:15 with our Board of Directors retaining the discretion as to whether to implement the reverse stock split and which exchange ratio to implement. In September 2020, the Company amended its articles of incorporation and enacted a reverse stock split of one share for each fifteen shares and the accompanying financials reflect the reverse stock split retroactively. The reverse stock split resulted in a decrease in authorized shares of all classes of stock from 615,000,000 to 315,000,000 shares consisting of 300,000,000 shares of common stock at a par value of $0.001 and 15,000,000 shares of preferred stock at a par value of $0.01 per share. Prior to the reverse stock split, the Company had 600,000,000 shares of common stock at a par value of $0.001, 15,000,000 shares of preferred stock at a par value of $0.20 per share. COMMON STOCK As of December 31, 2021 and June 30, 2021, the Company had 43,659,616 and 39,496,588 shares of common stock issued and outstanding, respectively. In the three months ending September 30, 2020, the holder of a convertible promissory note for $1,000,000 informed the Company that they had elected to convert the balance due to common shares at the agreed upon conversion price of $3.00 per share and 387,222 shares were issued representing the outstanding principal and accrued interest. In the three months ending September 30, 2020, the holder of a convertible promissory note for $200,000 informed the Company that they had elected to convert the balance due to common shares at the agreed upon conversion price of $3.75 per share and 56,000 shares were issued representing the outstanding principal and loan fee. In the three months ending September 30, 2020, the holder of a convertible promissory note for $200,000 informed the Company that they had elected to convert the balance due to common shares at the agreed upon conversion price of $3.75 per share and 56,000 shares were issued representing the outstanding principal and loan fee. In the three months ending September 30, 2020, the holder of a related party convertible promissory note of $1,300,000 elected to convert the debt into shares of the Company’s common stock at a rate of $0.75 per share for 1,733,334 shares. In the three months ending December 31, 2021, the Company issued 66,666 shares of common stock to a former employee as per their employment agreement. The common stock was distributed in two separate issuances at an average closing price of $1.56 per share and $104,000 in stock-based compensation was recorded. In the three months ending December 31, 2021, the Company issued 20,000 shares of common stock to a contractor providing marketing services as per their vendor agreement. The common stock was issued at a price of $2.01 per share and $40,000 in expenses relating to professional fees was recorded. PREFERRED STOCK The Company has authorized 15,000,000 shares as preferred stock, par value $0.01 series A, B, C and D, of which 5,000,000 shares have been designated as Series A preferred stock; 3,000,000 shares have been designated as Series B convertible preferred stock; 1,200,000 shares have been designated as Series C convertible preferred stock; and 2,500,000 shares have been designated as Series D convertible preferred stock. As of December 31, 2021, 720,000 shares of Series A Preferred Stock were issued and outstanding; 0 shares of Series B Preferred Stock were issued and outstanding; 0 shares of Series C Preferred Stock were issued and outstanding; and 0 shares of Series D Preferred Stock were issued and outstanding. As of June 30, 2021, 720,000 shares of Series A Preferred Stock were issued and outstanding; 0 shares of Series B Preferred Stock were issued and outstanding; 0 shares of Series C Preferred Stock were issued and outstanding; and 0 shares of Series D Preferred Stock were issued and outstanding. On May 10, 2021, the Company converted all Preferred Stock Series B, C, and D into Common Stock following its uplisting to the Nasdaq Capital Market. At the time of the conversion the Company had 2,495,000 shares of Series B Convertible Preferred Stock that were convertible into 594,048 shares of common stock at a price of $4.20 per share; 911,149 shares of Series C Convertible Preferred Stock convertible into 12,287,386 shares of Common Stock at $0.074 per share; and 1,979,000 shares of Series D Convertible Preferred Stock convertible into 5,277,334 shares of Common Stock at $0.375 per share for a total of 18,158,768 shares of Common Stock. STOCK PAYABLE In the fiscal year ended June 30, 2021, the Company recorded a stock payable of $1,210,000 relating to the acquisition of Redeeem, LLC. As per the asset purchase agreement dated May 21, 2021, 452,929 shares of common stock valued at $2.6715 per share were due to be issued to Redeeem’s employees and these shares were issued in the three months ending September 30, 2021. DEFERRED COMPENSATION On May 21, 2021, the Company entered into an agreement to acquire the assets and specific liabilities of fintech platform Redeeem, LLC for $2.6 million consisting of $1.2 million in cash, $166,000 in specific liabilities, and $1.2 million of the Company’s common stock. In addition, the Company agreed to provide equity to its employees to be vested over three years valued at $9,680,000 representing 3,623,433 shares of the Company’s common stock at conversion price of $2.6715 per share. Given the equity is contingent on the employees being employed and are vested over three years, the Company is treating this as deferred compensation and the expenses are recorded as the equity is vested. The vested portion of the deferred compensation was charged to additional paid-in capital and the expenses are recorded as stock-based compensation In August 2021, all 3,623,433 shares of the Company’s common stock was issued to Redeeem’s employees and held in an escrow account subject to the vesting schedule in the aforementioned escrow agreement. Based on the vesting schedule summarized below, 2,885,204 shares of the Company’s common stock was issued as of December 31, 2021 but not vested. The following table summarizes the deferred compensation recorded: Amount Unvested Shares Deferred compensation balance recorded at acquisition date $ 9,680,000 3,623,433 Vested portion of deferred compensation in fiscal year 2021 (362,000 ) (135,425 ) Unamortized deferred compensation at June 30, 2021 9,318,000 3,488,008 Vested portion of deferred compensation in six months ending December 31, 2021 (1,610,000 ) (602,804 ) Unamortized deferred compensation at December 31, 2021 $ 7,708,000 2,885,204 WARRANTS During the three months ended December 31, 2021, the Company issued warrants to a member of the Board of Directors to purchase 150,000 shares of the Company’s common stock at an exercise price of $1.24 per share. The warrants are valued at approximately $98,000 using the Black-Scholes model. During the three months ended December 31, 2020, the Company issued warrants to a certain aforementioned investor to purchase 40,000 shares of the Company’s common stock at $0.75 vested over three years in consideration for convertible note payables. Valued at $124,000, a total of $41,000 was expensed in both the three months ending December 31, 2020 and the three months ending December 31, 2021. As of December 31, 2021 and 2020, respectively, the Company has outstanding warrant shares of 8,261,223 with an intrinsic value of $2,944,984 and 8,359,851 warrant shares with an intrinsic value of $1,044,134. In February 2021, the Company decided to extend all warrants issued in association with its previous Series B Preferred Stock one year beyond their original expiration date. The Company considered recording the increase in the fair value associated with these new terms in the three months ending December 31, 2021 but determined that the change was not material and an adjustment was not necessary. The Company uses the Black-Scholes Model to determine the fair value of warrants granted. Option-pricing models require the input of highly subjective assumptions, particularly for the expected stock price volatility and the expected term of options. Changes in the subjective input assumptions can materially affect the fair value estimate. The expected stock price volatility assumptions are based on the historical volatility of the Company’s common stock over periods that are similar to the expected terms of grants and other relevant factors. The Company derives the expected term based on an average of the contract term and the vesting period taking into consideration the vesting schedules and future employee behavior with regard to option exercise. The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected term calculated at the date of grant. The Company has never paid any cash dividends on its common stock and the Company has no intention to pay a dividend at this time; therefore, the Company assumes that no dividends will be paid over the expected terms of warrants awards. The Company determines the assumptions used in the valuation of warrants awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at those grant dates. As such, the Company may use different assumptions for warrants granted throughout the year. The Company has utilized the following assumptions in its Black-Scholes warrant valuation model to calculate the estimated grant date fair value of the warrants during the six months ended December 31, 2021 and 2020: 2021 2020 Volatility - range 64.0 % 63.5% - 64.4 % Risk-free rate 0.9 % 0.2% - 0.3 % Contractual term 5.0 years 4.0 - 5.0 years Exercise price $ 1.24 $0.75 - $3.00 A summary of the warrants granted, exercised, forfeited and expired for the six months ending December 31, 2021 are presented in the table below: Number of Warrants Weighted-Average Exercise Price Weighted-Average Grant-Date Fair Value Aggregate Intrinsic Value of Outstanding Warrant Shares Weighted-Average Remaining Contractual Term (in years) Outstanding July 1, 2021 8,296,408 1.05 1.90 12,158,467 2.2 Granted 150,000 1.24 0.66 - - Exercised - - - - - Expired/Forfeited (185,185 ) 5.00 12.00 - - Outstanding December 31, 2021 8,261,223 0.98 1.63 2,944,984 1.7 Vested and exercisable June 30, 2021 7,055,736 0.88 1.50 2,667,549 1.9 Non-vested December 31, 2021 1,205,486 1.51 2.42 277,435 0.8 The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable warrants under the Company’s warrant plans as of December 31, 2021. Outstanding Warrant Shares Exercisable Warrant Shares Exercise price range Number of Warrant Shares Weighted average remaining contractual life Number of Warrant Shares Weighted average remaining contractual life $ 0.75 7,182,889 1.7 years 6,424,070 2.0 years $ 1.24 150,000 - - - $ 1.50 400,000 2.4 years 400,000 2.7 years $ 1.95 26,667 - - - $ 3.75 435,000 2.5 years 165,000 5.7 years $ 3.00 66,667 3.2 years 66,667 3.4 years 8,261,223 1.7 years 7,055,736 1.9 years A summary of the warrants granted, exercised, forfeited and expired for the six months ended December 31, 2020 are presented in the table below: Number of Warrant Shares Weighted-Average Exercise Price Weighted-Average Grant-Date Fair Value Aggregate Intrinsic Value of Outstanding Warrant Shares Weighted-Average Remaining Contractual Term (in years) Outstanding July 1, 2020 7,858,741 $ 1.52 $ 1.92 $ 9,234,295 3.0 Granted 590,000 0.75 3.15 1,967,500 4.3 Exercised - - - - - Expired/Forfeited (88,888 ) - - - - Outstanding December 31, 2020 8,359,851 1.24 1.87 11,037,350 2.8 Vested and exercisable December 31, 2020 7,241,518 1.22 1.69 8,367,683 2.6 Non-vested December 31, 2020 1,118,333 $ 1.39 $ 2.97 $ 2,669,667 3.7 The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable warrants under the Company’s warrant plans as of December 31, 2020. Outstanding Warrant Shares Exercisable Warrant Shares Exercise price range Number of Warrant Shares Weighted average remaining contractual life Number of Warrant Shares Weighted average remaining contractual life $ 0.75 7,188,333 2.8 years 6,341,667 2.7 years $ 1.50 400,000 3.4 years 266,667 3.5 years $ 1.95 26,666 4.8 years - - $ 2.25 6,666 4.8 years - - $ 3.00 76,667 0.6 years 3,333 4.6 years $ 3.75 368,333 3.9 years 230,000 4.0 years $ 6.00 381,333 0.2 years 381,333 0.2 years $ 27.00 18,518 0.6 years 18,518 0.6 years 8,359,851 2.8 years 7,241,518 2.6 years 2017 EQUITY INCENTIVE PLAN On June 13, 2017, the Board adopted and approved an amendment to the Troika Media Group, Inc. 2015 Employee, Director and Consultant Equity Incentive Plan (the “Equity Plan”), to change the name from M2 nGage Group, Inc. to Troika Media Group, Inc., in order to attract, motivate, retain, and reward high-quality executives and other employees, officers, directors, consultants, and other persons who provide services to the Company by enabling such persons to acquire an equity interest in the Company. Under the Plan, the Board (or the compensation committee of the Board, if one is established) may award stock options, either stock grant of shares of the Company’s common stock, incentive stock option under IRS section 422 (“ISO’s”) or a non-qualified stock option (“Non-ISO’s”) (collectively “Options”). The Plan allocates 3,333,334 shares of the Company’s common stock (“Plan Shares”) for issuance of equity awards under the Plan. As of December 31, 2021, the Company has granted, under the Plan, awards in the form of NQSO’s. 2021 EQUITY INCENTIVE PLAN On October 28, 2021, the Board adopted, and a majority of outstanding shares subsequently approved, the 2021 Employee, Director & Consultant Equity Incentive Plan (the “2021 Plan”). The prior Equity Plan did not have any remaining authorized shares. The 2021 Plan is intended to attract and retain employees, directors and consultants, to involve them to work for the benefit of the Company or its affiliated entities, and to provide additional incentive for them to promote the Company’s success. The 2021 Plan provides for the award of stock options, either incentive stock options (ISOs) or non-qualified stock options (NQSOs), restricted shares and restricted stock units (RSUs). The 2021 Plan authorized 12,000,000 shares of Common Stock for the issuance of awards under the 2021 Plan. As of the date of this report, an aggregate of 4,600,000 RSUs had been awarded to executive officers and directors and 1,500,000 RSUs had been awarded to employees. ISO’s Awards During the three months ended December 31, 2021, the Company issued options to certain employees to purchase 76,667 shares of the Company’s common stock between $1.49 and $3.75 per share which vested during various terms and were valued at $114,000. In regards to the options issued in the three months ending December 31, 2021, the Company recorded compensation of $0 for the vested portion of these options. The Company recorded compensation of $106,000 relating to the vested portion of options that were issued in previous periods for the three months ended December 31, 2021. The total compensation of the unvested options to be recognized in future periods is $896,000 and the weighted average remaining is 2.8 years. During the three months ended December 31, 2020, the Company did not issue additional options. The Company recorded compensation of $263,000 relating to the vested portion of options that were issued in previous periods for the three months ended December 31, 2020. The total compensation of the unvested options to be recognized in future periods is $596,000 and the weighted average remaining is 1.6 years. The Company uses the Black-Scholes Model to determine the fair value of Options granted. Option-pricing models require the input of highly subjective assumptions, particularly for the expected stock price volatility and the expected term of options. Changes in the subjective input assumptions can materially affect the fair value estimate. The expected stock price volatility assumptions are based on the historical volatility of the Company’s common stock over periods that are similar to the expected terms of grants and other relevant factors. The Company derives the expected term based on an average of the contract term and the vesting period taking into consideration the vesting schedules and future employee behavior with regard to option exercise. The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected term calculated at the date of grant. The Company has never paid any cash dividends on its common stock and the Company has no intention to pay a dividend at this time; therefore, the Company assumes that no dividends will be paid over the expected terms of option awards. The Company determines the assumptions used in the valuation of Option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at those grant dates. As such, the Company may use different assumptions for options granted throughout the year. The Company has utilized the following assumptions in its Black-Scholes options valuation model to calculate the estimated grant date fair value of the options during the six months ended December 31, 2021 and 2020: 2021 2020 Volatility - range 64.2%–64.9 % 64.8 % Risk-free rate 0.9–1.2% % 0.3 % Contractual term 3.0 years 3.0 years Exercise price $ 1.49 - $3.75 $ 3.75 A summary of the options granted, exercised, forfeited and expired for the six months ending December 31, 2021 are presented in the table below: Number of Options Weighted-Average Exercise Price Weighted-Average Grant-Date Fair Value Aggregate Intrinsic Value of Outstanding Option Shares Weighted-Average Remaining Contractual Term (in years) Outstanding July 1, 2021 3,088,333 $ 1.13 $ 1.06 1,829,999 0.4 Granted 720,169 3.46 1.49 - 2.8 Exercised - - - - - Expired/Forfeited - - - - - Outstanding December 31, 2021 3,808,502 1.39 1.13 1,044,134 0.8 Vested and exercisable December 31, 2021 2,912,778 0.92 1.11 1,009,056 0.2 Non vested December 31, 2021 895,724 $ 2.91 $ 1.39 $ 35,078 2.8 The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable options under the Company’s warrant plans as of December 31, 2021. Outstanding Option Shares Exercisable Option Shares Exercise price range Number of Option Shares Weighted average remaining contractual life Number of Option Shares Weighted average remaining contractual life $ 0.75 2,546,667 0.2 2,594,444 0.1 $ 1.49 10,000 2.9 - - $ 1.50 200,000 - 200,000 - $ 2.08 258,334 2.4 - - $ 2.61 383,500 3.5 - - $ 2.84 1,667 3.5 - - $ 3.75 408,334 1.5 118,333 1.2 3,808,502 0.8 2,912,778 0.2 A summary of the options granted, exercised, forfeited and expired for the six months ended December 31, 2020 are presented in the table below: Number of Option Shares Weighted-Average Exercise Price Weighted-Average Grant-Date Fair Value Aggregate Intrinsic Value of Outstanding Option Shares Weighted-Average Remaining Contractual Term (in years) Outstanding July 1, 2020 3,377,222 $ 1.10 $ 1.06 $ 2,030,000 0.7 Granted 76,667 3.75 1.61 - 2.8 Exercised - - - - - Forfeited - - - - - Expired (143,333 ) - - - - Outstanding December 31, 2020 3,310,556 1.10 1.01 1,830,000 0.5 Vested and exercisable December 31, 2020 2,714,893 0.80 0.89 1,351,901 0.3 Non-vested December 31, 2020 595,663 $ 2.49 $ 1.82 $ 478,099 1.6 The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable options under the Company’s warrant plans as of December 31, 2020. Outstanding Option Shares Exercisable Option Shares Exercise price range Number of Option Shares Weighted average remaining contractual life Number of Option Shares Weighted average remaining contractual life $ 0.75 2,768,889 0.3 2,543,782 0.2 $ 1.50 200,000 0.8 166,667 0.7 $ 3.75 341,667 2.2 4,444 1.3 3,310,556 0.5 2,714,893 0.3 |